The concomitant utilization of oxycodone HCl with all cytochrome P450 3A4 inhibitors may bring about an increase in oxycodone plasma concentrations, which could maximize or lengthen adverse reactions and should trigger potentially deadly respiratory despair. In addition, discontinuation of a concomitantly utilized cytochrome P450 3A4 inducer could